ArticleLeukemia2017
JAK2-V617F activates β1-integrin-mediated adhesion of granulocytes to vascular cell adhesion molecule 1.
Article in Leukemia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 28 citations in OpenAlex.
- Activation of integrin signaling up-regulates pro-inflammatory cytokines in JAK2-V617F positive hematopoietic cells.Cell communication and signaling : CCS · 2025Article
- Clonal Hematopoiesis and Thrombosis.American journal of hematology · 2025Review
- Malignant JAK-signaling: at the interface of inflammation and malignant transformation.Leukemia · 2025Review
- Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Neutrophil-specific expression of JAK2-V617F or CALRmut induces distinct inflammatory profiles in myeloproliferative neoplasia.Journal of hematology & oncology · 2024Article
- Adrenal infarction with latent myelodysplastic/myeloproliferative neoplasm, unclassifiable withClinical case reports · 2024Article
- Splanchnic Vein Thrombosis in Myelofibrosis-An Underappreciated Hallmark of Disease Phenotype.International journal of molecular sciences · 2023Review
- Thromboinflammation in Myeloproliferative Neoplasms (MPN)-A Puzzle Still to Be Solved.International journal of molecular sciences · 2022Review
- Review
- The Role of Neutrophilic Granulocytes in Philadelphia Chromosome Negative Myeloproliferative Neoplasms.International journal of molecular sciences · 2021Review
- Pathogenesis of cardiovascular events in BCR-ABL1-negative myeloproliferative neoplasms.Leukemia · 2021Review
- Emerging Role of Neutrophils in the Thrombosis of Chronic Myeloproliferative Neoplasms.International journal of molecular sciences · 2021Review
- Role of β1 integrin in thrombocytopoiesis.Faculty reviews · 2021Review
- Evidence of Clonal Hematopoiesis and Risk of Heart Failure.Current heart failure reports · 2020Review
- High circulating levels of MPO-DNA are associated with thrombosis in patients with MPN.Leukemia · 2019Article
- Review
- Clonal Hematopoiesis and Its Impact on Cardiovascular Disease.Circulation journal : official journal of the Japanese Circulation Society · 2018Review
- JAK2-V617F promotes venous thrombosis through β1/β2 integrin activation.The Journal of clinical investigation · 2018Article
- Neutralize the neutrophils! Neutrophil β1/β2 integrin activation contributes to JAK2-V617F-driven thrombosis.The Journal of clinical investigation · 2018Article
- Thrombotic and Hemorrhagic Issues Associated with Myeloproliferative Neoplasms.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.